



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/120,030	07/21/1998	BETH P GOLDSTEIN	70021.0022USU1	1743
72960	7590	12/28/2010		
Casimir Jones, S.C. 2275 DEMING WAY, SUITE 310 MIDDLETON, WI 53562			EXAMINER BORIN, MICHAEL L	
			ART UNIT	PAPER NUMBER
			1631	
			MAIL DATE	DELIVERY MODE
			12/28/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/120,030

Applicant(s)

GOLDSTEIN ET AL.

Examiner

Michael Borin

Art Unit

1631

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11/05/2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 67-79,81,83,84,86-89,92 and 93 is/are pending in the application.
- 4a) Of the above claim(s) 67-78 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 79,81,83,84,86-89,92 and 93 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1631

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/05/2010 has been entered.

Status of the claims

Claim 79 is amended. Claims 80,82,94 are canceled. Claims 67-79,81,83,84,86-89,92,93 are pending. Claims 67-78 remain withdrawn from consideration.

Applicant's arguments have been fully considered but were not deemed persuasive . It is noted that the arguments regarding art rejection of record are taken, verbatim, from the previous applicant's communication of 03/01/2010. The arguments are and were not deemed persuasive and have been

Art Unit: 1631

already addressed on multiple occasions in the preceding Office actions and/or in the Board decision. The rejection is maintained.

The following rejections are either reiterated. They constitute the complete set presently being applied to the instant application.

Claim Rejections - 35 USC § 103.

Art Unit: 1631

Claims 79,81,83,84,86-89,92,93 are rejected under 35 U.S.C. 103(a) as unpatentable over Zygmunt, and Goldberg and Stark, and further in view of Oldham. The rejection is maintained for the reasons set forth for claims 79-84,86-89,92-94 in the previous Office action.

Claim 79 is amended to address two limitations: 1) treating staphylococcal infection which is a methicillin resistant staphylococcal infection, and 2) organ being selected from the group consisting of heart, blood, kidney, lung, bone and meninges. Both limitations have been reflected in the prior rejections. Therefore, the rejection of record is repeated, with the limitations added with the amendment of 11/05/2010 being highlighted.

Art Unit: 1631

The instant claims are drawn to method of treating staphylococcal infection in a human subject comprising administration of a recombinantly produced lysostaphin in a dose from 3 to 25 mg/kg/day.

Zygmunt

Zygmunt et al is a general reference reviewing properties of lysostaphin, its *in vitro* and *in vivo* applications, and various ways of administration. The reference teaches that lysostaphin is effective against a wide variety of staphylococcal infection, and is more potent than penicillins. The reference describes treatment of staphylococcal infections in **various organs, such as kidney, heart valve** (pages 319-325). The ways of administration are both systemic and topical (pages 319-324). The dosages of lysostaphin vary depending on the ways of administration; thus reference cites use of single doses in the range of 0.5 to 50 mg/kg (p. 320, Table 4), or multiple doses in the range of 0.5 to 50 (p.523, bottom addressing study of Goldberg et al; see discussion of Goldberg reference below). Thus, both the dosage and ways of administration are result-effective variables which may be optimized by an artisan in a course of routine

Art Unit: 1631

optimization. Combined therapy with other antimicrobials, such as methicillin, augments effect of lysostaphin (p. 322). The reference also teaches pharmaceutical compositions comprising lysostaphin.

Zygmunt reviews a number of studies of the efficacy of lysostaphin in treating established staphylococcal infections in animals, including Goldberg's study, discussed below (Zygmunt 318-324).

In another reviewed study, 100% of mice infected with an otherwise lethal intraperitoneal staphylococcal infection survived when treated with a single intravenous dose of lysostaphin, in contrast to 53% survival in mice treated with penicillin G instead (Zygmunt 319).

In yet another reviewed study, mice with established **methicillin**-resistant staphylococcal renal abscesses demonstrated the effectiveness of a single dose of lysostaphin followed by daily doses of methicillin on succeeding days, "suggest[ing] that a single exposure to lysostaphin may increase the susceptibility of staphylococci to eventual destruction by methicillin" (Zygmunt 322-323).

In addition, Zygmunt suggests that "lysostaphin could provide a reserve mode of therapy in dire situations" (Zygmunt 330), "[s]ince none of the clinically available antibiotics is able to lyse large numbers of staphylococci regardless of their metabolic state with the effectiveness of lysostaphin" (id.), and further

Art Unit: 1631

suggests that lysostaphin "be tested in those instances of human staphylococcal disease where it is imperative to decrease the number of microorganisms present in infected tissues (endocarditis, infected vascular grafts, atrioventricular shunts, etc.)" (id.).

Zygmunt also suggests that it could be beneficial to administer lysostaphin in combination with a semisynthetic penicillin (Zygmunt 330). The underlying rationale is that "initial lysostaphin therapy may lower the titers of staphylococci within established lesions sufficiently to allow conventional antimicrobials to exert a therapeutic effect and to enable the host's defense mechanisms to function more effectively. In addition, the rapid elimination of circulating staphylococci in cases of staphylococcal bacteremia may prevent metastatic infection" (id. at 330-331).

With respect to dosage levels in humans, Zygmunt suggests that "short-term intravenous doses to man in the range of 10 mg/kg b.i.d. [i.e., twice a day] of lysostaphin might be expected to cause no serious toxic effects" (Zygmunt 327).

Goldberg

Art Unit: 1631

Goldberg et al teach treatment of staphylococcal infection in dogs with lysostaphin used intravenously at dosages 5-50 mg/kg. The administration was done multiple times, at intervals 1 to 24h. Treatment courses consisted of 1 to 23 injections over periods of 5h to 6.5 days. When recalculated to the amounts in mg/kg/day, i.e., as used in the instant claims, dogs 4, 5, 7, and 10 received 35.4, 31.6, 17.6, and 13 mg/kg/day, respectively¹. Although lysostaphin administration was followed in relapse in some dogs (dogs 7 and 10), administration of lysostaphin caused from substantial reduction to complete clearance of infection. See Table 1. Lysostaphin treatment was effective in treatment of infection in lung, liver, spleen, kidney, and aortic and mitral valves. Heart valves were the most easily sterilized tissue. Adverse reactions to lysostaphin were not observed. See abstract and Table 1.

Note, that the amount of lysostaphin which resulted in successful treatment of dogs (no relapse) of dogs 4 and 5 (Table 4), is only marginally different from the claimed amount of 3-25 mg/kg/day of recombinantly produced lysostaphin for treatment of humans as claimed.

¹ All amounts hereinafter are recalculated into mg/kg/day as (Mean dose)x(No. doses)/(No days treated) as suggested by applicant in response filed 10/20/2003

Art Unit: 1631

Goldberg describes a study wherein thirteen dogs infected with experimental acute staphylococcal endocarditis were treated with lysostaphin "administered intravenously in doses of 5 to 50 mg/kg at intervals of 1 to 24 hr. Treatment courses consisted of 1 to 23 injections over periods of 5 hr to 6.5 days" (Goldberg Abstract).

All thirteen dogs in Goldberg's study improved clinically after initial therapy. Three experiments were terminated while the dogs were improving, five dogs became clinically well, and five relapsed (Goldberg Abstract). "One relapsed dog [] received only a single 50 mg/kg dose, and three other relapsed dogs [] received the smallest individual doses in the series of 13 dogs" (id. at 48, col. 1). The fifth dog that relapsed did so after a surgical accident (id.).

"Regardless of the size of the dose, [lysostaphin] therapy resulted in a [substantial] decrease in the number of staphylococci circulating in the blood" and "[q]uantitative culture of tissues showed that lysostaphin treatment resulted in decreased numbers of staphylococci in lung, liver, spleen, kidney, and aortic and mitral valves[:]" [h]eart valves were the most easily sterilized tissue" (Goldberg Abstract).

"Adverse reactions to lysostaphin were not observed" (Goldberg Abstract).

Art Unit: 1631

"[L]ysostaphin's selective action against *S. aureus* and no other bacteria would permit its use

without the fear of super-infection common to most antibiotics which alter the bacterial flora of man"

(Goldberg 51, col. 2). Another advantage of lysostaphin over other antibiotics is its "rapid killing at any stage of growth" (Goldberg 51, col. 2).

Zygmunt and Goldberg references do not teach administration of lysostaphin to humans.

Stark

Stark et al describes systemic administration of lysostaphin to a man suffering from staphylococcal pneumonia resulting from terminal unresponsive leukemia. The reference demonstrates that parenteral systemic administration of lysostaphin reduces bacteremia caused by strain of *S. Aureus* which proved to be resistant to methicillin, vancomycin and cephalothin. Single treatment with lysostaphin resulted in a complete clearance of microorganisms from pustule sites. The treatment also removed staphylococci from blood, lungs, or abscess site.

Art Unit: 1631

Stark teaches that lysostaphin effectively cleared methicillin-resistant Staph. aureus (MRSA) from infected abscesses in a neutropenic patient (Stark 240).

"Despite potential immunogenicity, controlled trials of lysostaphin may be indicated now as adjunctive therapy in human staphylococcal infections in which mortality and morbidity remain high, as in overwhelming or resistant involvement of lung, liver, brain, endocardium, and bone by Staph. aureus" (Stark 240).

The references above do not teach recombinant lysostaphin or use thereof. It is well established in the art that recombinant way of production of proteins is easier and more effective than non-recombinant methods (such as organic synthesis or purification). Oldham reference is used to demonstrate that lysostaphin can be produced recombinantly and that the product produced thereby has high antimicrobial activity similar to that of the natural product.

Art Unit: 1631

Oldham

Oldham et al teaches that lysostaphin can be produced recombinantly and demonstrates that recombinant lysostaphin, at low concentration of 5 µg/ml, is effective against *S. Aureus* in mammary tissue.

See abstract. Note that administration to mammary tissue reads on the instantly claimed systemic administration, as the latter encompasses direct delivery to organs through injection (see specification, page 6, lines 31-32)

The references of record establish that one of skill in this art would have recognized, and been accustomed to weighing, the relative risks and benefits of antimicrobial therapy (as demonstrated in Zygmund). That being the case, administering lysostaphin to humans to treat established staphylococcal infections would have been obvious to one of skill in the art at the time of the invention (and indeed was explicitly suggested by persons of skill in the art (as addressed in Zygmund, p. 330,331 cited above), despite lysostaphin's potential for immunogenicity, given the recognition in the art that staphylococcal

Art Unit: 1631

infections resistant to conventional antibiotics (e.g., **methicillin-resistant** *Staph. aureus* (MRSA) infections)

are often sensitive to lysostaphin, the recognition that it is imperative to rapidly decrease the sheer number

of microorganisms present in infected tissues like heart valves and in infections associated with devices like

atrioventricular shunts, the recognition that "none of the clinically available antibiotics is able to lyse large

numbers of staphylococci regardless of their metabolic state with the effectiveness of lysostaphin" (Zygmund,

p. 330, cited above), and the recognition that lysostaphin is highly selective and can be used without fear of

super-infection common to most antibiotics which affect the bacterial flora of humans less-selectively

(Goldberg, p. 51, col. 2, cited above).

Further, a short-term intravenous administration of lysostaphin in the range of 10 mg/kg, twice a day

- a protocol that meets the requirement of the claims - would have been obvious, given Zygmunt's

suggestion that this particular protocol would not be expected to cause adverse reactions in humans

(Zygmund, p. 327, cited above).

Further, it would have been obvious for one of skill in the art to administer recombinant

lysostaphin, rather than native lysostaphin, given the availability of the recombinant product and its

Art Unit: 1631

comparability to native lysostaphin (as demonstrated by Oldham).

The invention of claims 79,81,83,84,86-89,92,93 would have been obvious over the teachings of Zygmunt, Goldberg, Stark, Oldham, and Dixon. It would have been obvious for one of skill in the art to have administered lysostaphin in combination with another antimicrobial agent, given the recognition that lysostaphin acts quickly to kill most, but not necessarily all, of the Staphylococci present in an established lesion, while at the same time, rendering the remaining organisms more susceptible to other, conventional antimicrobials

Therefore, the prior art teaches that lysostaphin is effective both *in vitro*, in animal studies, and in humans. In regard to multiple administration to humans, as Goldberg teaches that lysostaphin is effective in animal studies when taken either in a single dose or repetitively, it would be obvious to select an appropriate regime of administration in humans as well. In regard to the particular dosage ranges, first, Goldberg teaches dosage range that overlaps with the claimed dosage ranges. Second, if there are any differences between dosage ranges as claimed and that of the prior art, the differences would be appear

Art Unit: 1631

minor in nature; in addition as the dosage is an result-effective variable, as can be clearly seen from, e.g., Goldberg, selection of the dosage, protocol and route of administration will be obvious to one skilled in the art as a result of routine optimization.

With regard to various locations of treatment, as Zygmunt teaches that lysostaphin is effective against more than 300 staphylococcus species and suggests its wide use at various locations, and as Stark suggests use of lysostaphin for treatment of human staphylococcal infections in lung, liver, brain, endocardium, and bone, it would have been obvious to an artisan to apply this versatile antimicrobial at the sites which require antimicrobial treatment with the expectation, in the absence of evidence to the contrary, that such treatment will be successful.

The Board of Appeals and Interferences, considering claims previously presented in this application, provided the following considerations: